(E)-3-phenyl-2-propene-1-yl 3-aminocrotonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-phenyl-2-propene-1-yl 3-aminocrotonate
• 英文别名: cinnamyl 3-aminocrotonate；3-Amino Crotonic Acid Cinnamyl Ester；[(E)-3-phenylprop-2-enyl] (Z)-3-aminobut-2-enoate
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: GOWWDIWBLHYGMJ-GZPHBSKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-phenyl-2-propene-1-yl 3-aminocrotonate 、 3-糠醛 、 2-氰基乙酰乙酸乙酯 以66.8%的产率得到(3-phenyl-2-propene-1-yl) 3-(2-cyanoethyl) 2,6-dimethyl-4-(furan-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  Dihydropyridine derivative

  摘要：

  二氢吡啶衍生物具有以下结构式，其类似物和药学上可接受的盐具有选择性抑制N型钙通道作用的活性。它们被用作治疗与N型钙通道相关的各种疾病，如脑梗死发作后急性期内由缺血引起的脑病、脑出血或类似疾病、阿尔茨海默病等。

  公开号：

  US06350766B1
• 作为产物：
  描述：

  (E)-(3-phenylallyl) 3-oxo-butyrate 在 ammonium acetate 作用下， 以 异丙醇 为溶剂， 生成 (E)-3-phenyl-2-propene-1-yl 3-aminocrotonate
  参考文献：
  名称：

  Structure–activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels

  摘要：

  Cilnidipine is a 1,4-dihydropyridine derived L/N-type calcium channel dual blocker possessing neuroprotective and analgesic effects which are related to its N-type calcium channel inhibitory activity. In order to find specific N-type calcium channel blockers with the least effects on cardiovascular system, we performed structure-activity relationship study on APJ2708, which is a derivative of cilnidipine, and found a promising N-type calcium channel blocker 21b possessing analgesic effect in vivo with a 1600-fold lower activity against L-type calcium channels than that of cilnidipine. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.021

文献信息

• [EN] Drp1-FILAMIN COMPLEX FORMATION INHIBITORS<br/>[FR] INHIBITEURS DE FORMATION DE COMPLEXE DRP1-FILAMINE
  申请人：UNIV KYUSHU NAT UNIV CORP

  公开号：WO2020241638A1

  公开（公告）日：2020-12-03

  Compounds represented by formula (I) below and pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.

  由下式（I）表示的化合物及其药理学上可接受的盐和溶剂化物；含有它们的药物组合物和动态蛋白相关蛋白1（Drp1）-filamin复合物形成抑制剂；以及用于作为预防或治疗剂的化合物、盐、溶剂化物、药物组合物和（Drp1）-filamin复合物形成抑制剂。
• Novel dihydropyridine derivative
  申请人：AJINOMOTO CO., INC.

  公开号：US20020111494A1

  公开（公告）日：2002-08-15

  Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc. 1

  以下公式的二氢吡啶衍生物，其类似物和药学上可接受的盐具有选择性抑制N型钙通道作用的活性。它们被用作治疗与N型钙通道相关的各种疾病，例如在脑梗死、脑出血等急性期缺血引起的脑病、阿尔茨海默病等方面。
• Process for preparing novel dihydropyridine derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0173126A1

  公开（公告）日：1986-03-05

  Process for preparing novel dihydropyridine deriva-- tives and salts thereof represented by the general formula (1). [wherein R', R2 and R4 are each a lower alkyl group; R3 is a nitro group or a lower alkyl group which may have 1 to 3 halogen atoms as the substituents; R5 is a phenyl group which may have 1 to 3 substituents selected from the group consisting of a lower alkoxy group, a halogen atom, a lower alkylthio group, a hydroxyl group, a lower alkonyloxy group, a tetrahydropyranyloxy group, a lower alkoxy-lower alkoxy group; and A is an unsaturated straight- or branched-chain hydrocarbon residue]. The novel dihydropyridine derivatives and salts thereof are useful as coronary blood flow improving agents such as coronary vasodilator, hypotensive agent, prophylaxis and treating agents for thrombosis, phosphodiesterase inhibitory agents, peroxidized lipid metabolism lowering agents, antiinflammatory agents as well as anti-tumorigenic agents.

  由通式（1）表示的新型二氢吡啶衍生物及其盐的制备方法。 [其中 R'、R2 和 R4 各为低级烷基；R3 为硝基或低级烷基，其取代基可为 1 至 3 个卤素原子；R5 是苯基，可具有 1 至 3 个取代基，这些取代基选自低级烷氧基、卤素原子、低级烷硫基、羟基、低级烷酰氧基、四氢吡喃氧基、低级烷氧基-低级烷氧基组成的组；以及 A 是不饱和直链或支链烃残基]。新型二氢吡啶衍生物及其盐类可用作冠状动脉血流改善剂，如冠状动脉血管扩张剂、降血压剂、血栓预防和治疗剂、磷酸二酯酶抑制剂、过氧化脂质代谢降低剂、抗炎剂以及抗肿瘤剂。
• 1,4-dihydropyridine derivatives
  申请人：FUJIREBIO INC.

  公开号：EP0400660A1

  公开（公告）日：1990-12-05

  1,4-Dihydropyridine derivatives of formula (I): wherein Ar1 and Ar2 each represent an unsubstituted or substituted aromatic hydrocarbon or aromatic heterocyclic group; and R1 represents -C02R2, -SO2R3, -COR4, -CON(R5)2, -CN or -NO2 in which R2 is hydrogen, a straight chain, branched chain or cyclic saturated hydrocarbon group, which may have a substituent or a straight chain, branched chain or cyclic unsaturated hydrocarbon group having 2 to 10 carbon atoms, which may have a substituent, R3 is an alkyl group having 1 to 4 carbon atoms, R4 is an alkyl group having 1 to 4 carbon atoms or a phenyl group; and R5 is an alkyl group having 1 to 4 carbon atoms.

  式(I)的 1,4-二氢吡啶衍生物： 其中 Ar1 和 Ar2 各自代表未取代或取代的芳香烃或芳香杂环基团； 和 R1 代表-C02R2、-SO2R3、-COR4、-CON(R5)2、-CN 或 -NO2，其中 R2 是氢、直链、支链或环状饱和烃基（可有取代基）或具有 2 至 10 个碳原子的直链、支链或环状不饱和烃基（可有取代基），R3 是具有 1 至 4 个碳原子的烷基，R4 是具有 1 至 4 个碳原子的烷基或苯基； R5 是具有 1 至 4 个碳原子的烷基。
• NOVEL DIHYDROPYRIDINE DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP0985667A1

  公开（公告）日：2000-03-15

  Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc.

  下式的二氢吡啶衍生物、其类似物及其药学上可接受的盐类具有选择性抑制 N 型钙通道作用的活性。它们可用于治疗与 N 型钙通道有关的各种疾病，如脑梗塞、脑出血等发病后急性期缺血引起的脑病、阿尔茨海默病等。